Image

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Recruiting
18 - 75 years of age
Both
Phase 2

Powered by AI

Overview

The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)

Eligibility

Inclusion Criteria:

  1. Subject's written informed consent
  2. Male or female subjects aged ≥18 and ≤75 years
  3. A documented history of physician-diagnosed asthma for at least 1 year and with diagnosis before the age of 50 years
  4. Stable asthma therapy: a stable maintenance treatment with medium to high dose of inhaled corticosteroids plus long acting β2 agonists for at least 3 months prior to screening
  5. A prebronchodilator FEV1 ≤80% of the predicted normal value
  6. Bronchodilator responsiveness after inhalation of salbutamol or equivalent
  7. Evidence of poorly controlled or uncontrolled asthma as based on an ACQ-7 score ≥1.5
  8. History of asthma exacerbations : at least 1 asthma exacerbation leading to hospitalisation or 2 or more asthma exacerbations within the last 12 months
  9. A cooperative attitude and ability to use inhalers and to comply with study procedures

Exclusion Criteria:

  1. e-Diary completion compliance <75% during run-in
  2. History of near fatal asthma or of a past hospitalisation for asthma in intensive care unit
  3. Recent exacerbation or respiratory tract infection within 4 weeks prior to screening visit or during the run-in period
  4. Subjects using systemic corticosteroids medication in the 4 weeks or slow-release corticosteroids in the 12 weeks prior to randomisation
  5. Asthma requiring use of biologics
  6. Respiratory disorders other than asthma: subjects with known respiratory disorders other than asthma
  7. Subjects with a history of lung volume resection
  8. Current smokers, ex-smokers with a smoking history of ≥10 pack-years or current use of inhaled or oral cannabis products.
  9. Subjects with cancer or history of cancer
  10. Subjects with cardiovascular diseases
  11. Subjects with any abnormal and clinically significant 12-lead ECG
  12. Subjects with previous medical history, evidence of an uncontrolled intercurrent illness, or any clinically relevant abnormal findings in haematology, clinical chemistry, or urinalysis
  13. Subjects with a diagnosis of depression, generalised anxiety disorder, suicidal ideation or behaviour
  14. Patients mentally or legally incapacitated or patients accommodated in an establishment
  15. Subjects with liver diseases
  16. Drugs with hepatoxicity potential
  17. Subjects with contra-indications to IMPs:
  18. Subjects with history alcohol/drug abuse
  19. Subjects with major surgery in the 3 months prior to screening visit or planned during the trial
  20. Subjects treated with non-potassium sparing diuretics, nonselective β-blocking drugs, quinidine, quinidine like anti-arrhythmic, or any medication with a QTc prolongation potential or a history of QTc prolongation
  21. Subjects treated with monoamine oxidase inhibitors (MAOIs) and tricyclic anti-depressants
  22. Subjects receiving any therapy that could interfere with the study drugs
  23. Participation in another investigational trial
  24. Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 2 weeks
  25. Subjects having received a vaccination within 2 weeks prior to screening or during the run-in period.
  26. For females only: pregnant or lactating women

Study details

Uncontrolled Asthma

NCT06029595

Chiesi Farmaceutici S.p.A.

12 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.